Cullinan Therapeutics

What would Dr. Ricardo Grieshaber-Bouyer, Professor of Clinical Systems Immunology and Head of the Clinical Trials Unit at FAU Erlangen-Nuremberg, like the world to look like for a patient with rheumatoid arthritis??? ? Jeff Jones, Chief Medical Officer, recently sat with Dr. Grieshaber-Bouyer to discuss his clinical experience in rheumatic diseases, the potential of T cell engagers in treating autoimmune diseases, and his hopes for breaking through the ceiling of what current therapeutic approaches offer.

Today at 2:30 p.m. ET, Patrick A. Baeuerle, co-founder and Chief Scientific Advisor, will present at Society for Immunotherapy of Cancer (SITC)’s Immuno-Oncology Drug Development Summit.??? ? Known for his contributions to the field of immuno-oncology for leading the development of bispecific T cell engagers, Patrick’s #SITC presentation will focus on T cell engagers for liquid tumors.? ? Click for more details: https://bit.ly/3MGlXC3

The convergence of scientific innovation in #oncology and #immunology is accelerating our opportunities to advance new standards of care for patients with #cancer and #autoimmune diseases. ? ? Hear from Jennifer Michaelson, Chief Scientific Officer, on how Cullinan is applying oncology breakthroughs to research in autoimmune diseases in a panel discussion at the #FierceBiotechSummit. Learn more: https://bit.ly/3ZAdmIP

At #ESMO24, we presented the latest clinical findings from our Phase 2b study of zipalertinib which demonstrated positive results in heavily pretreated patients with non-small cell #LungCancer harboring EGFR exon 20 insertion mutations, who have progressed on or after treatment with amivantamab. With limited treatment options available for these patients, we look forward to advancing our comprehensive development plan for zipalertinib as part of our mission to bring new standards of care to patients. Learn more: https://bit.ly/4e2yk7A

Today at 10:20 AM ET, Nadim Ahmed, President and CEO, and Jeff Jones, Chief Medical Officer, will participate in a fireside chat at the Cantor Fitzgerald Global Healthcare Conference in New York, NY.? ? A live webcast and recording will be available here:?https://bit.ly/4bD5WHU #CantorHCC

This #GynecologicCancerAwarenessMonth, we’re shedding a light on the need for more awareness and clinical research for cancers that affect the female reproductive system. ? ? With few treatment options currently available, our team is passionate about our research to pursue novel approaches to treating endometrial and cervical cancers. Learn more: https://bit.ly/3Xghixd

Today, we announced approval from the Human Research Ethics Committee in Australia to begin our global Phase 1 trial of CLN-978, a CD19xCD3 bispecific T cell engager, for the treatment of systemic lupus erythematosus (SLE).? ? SLE affects approximately 430,000 individuals globally. Currently available treatments do not routinely induce treatment-free remission, with most patients requiring lifelong immune suppression that treats symptoms without modifying the course of disease.? ? Today marks an important step in our efforts to bring a potential new treatment option to patients around the world living with SLE.? ? Learn more: https://bit.ly/4d8IL8c

Today, we announced the submission of an Investigational New Drug Application for CLN-978, a CD19xCD3 bispecific T cell engager, to treat systemic lupus erythematosus (SLE) to the U.S. FDA. ?? ? Currently available SLE treatments do not routinely induce treatment-free remission. Our goal is to bring a new therapeutic option to the 160,000+ patients impacted by SLE in the U.S.?? ? Learn more: https://bit.ly/3B97MTx

Today, we shared positive updated results from our pivotal Phase 2b REZILIENT1 trial in patients receiving zipalertinib after prior treatment with amivantamab at ESMO - European Society for Medical Oncology Congress. We also shared that enrollment of this trial has been completed ahead of schedule. Learn more: https://bit.ly/4e2yk7A ? #ESMO24?

While cytokines play a key role in immune system activation, clinical adoption of cytokine-based therapies for the treatment of cancer has been limited due to low response rates and severe toxicities. ? ? In a perspective piece in Frontiers in Oncology, our scientists discuss the potential of intratumoral delivery of cytokines optimized for tumor retention as a therapeutic solution that may address these limitations. ? ? We’re investigating the clinical potential of this approach with CLN-617, a collagen-binding fusion protein, that co-delivers IL-2 and IL-12 on a single molecule.? ? Read the full perspective: https://bit.ly/4716RjO?? ? #Immunotherapy #CancerResearch #FrontiersInOncology ?